NSB
5mill cash, 7mill mcap
should rerate here
is pleased to advise that the Company has filed a Pre-Investigation New Drug Application (‘preIND’) meeting request with the US Food and Drug Administration (‘FDA’) for EmtinB for
treatment of advanced glaucoma in adults.
Dr Keating was first
appointed as Director of the Company on 5 December 2023 and is an experienced
entrepreneur and CEO having co-founded and led ResApp Health from start-up to its ultimate
acquisition by Pfizer for $180 million.
- Forums
- ASX - Day Trading
- Morning Trading April 2
Morning Trading April 2, page-71
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)